Tyra Biosciences is exploding higher as investors react to the company's announcement that it will host a conference call on September 9, 2026, to discuss initial clinical results from the SURF302 Phase 2 study of oral dabogratinib. The upcoming presentation of data for this treatment targeting IR NMIBC has clearly captured market attention, driving significant buying interest ahead of the scheduled event. While the broader healthcare sector saw various regulatory updates and approvals, the specific anticipation surrounding the dabogratinib results serves as the primary catalyst for the stock's move today.